BridgeBio Pharma Inc. (BBIO) Misses Q4 EPS by 28c

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($1.00), $0.28 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $154.2 million versus the consensus estimate of $146.16 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Ticketplus files for IPO with shares priced between $13-$15
• Venu Holding enters $250 million at-the-market stock offering agreement